TY - JOUR
T1 - Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid
AU - Bhalla, Sheena
AU - Joshi, Deval
AU - Bhullar, Shaminder
AU - Kasuga, Daniel
AU - Park, Yeonhee
AU - Kay, Christine N.
PY - 2013/7
Y1 - 2013/7
N2 - Aims: The purpose of this study was to determine the long-term efficacy and safety of valproic acid (VPA) treatment in patients with pigmentary retinal dystrophies. Methods: A retrospective chart review was conducted on 31 patients with a diagnosis of pigmentary retinal dystrophy prescribed VPA at a single centre. Visual field (VF), visual acuity (VA), length of treatment, liver enzymes and side effects were analysed. VF areas were defined using Goldmann VF (GVF) tracings recorded before, during and after VPA treatment using the V4e isopter for each eye. Using custom software, planimetric areas of VF were calculated. Results: Five of the patients (10 eyes) had two Goldmann VF tracings, allowing comparison between baseline and follow-up VF. After 9.8 months of VPA, VF decreased by 0.145 cm2 (26.478%) (p=0.432). For 22 of the patients (41 eyes), VA data was available, and logarithm of the minimum angle of resolution (logMAR) score changed by 0.056 log units (representing a decline in VA) after 14.9 months on VPA (p=0.002). Twelve patients (38.7%) reported negative side effects related to VPA use. Conclusions: VPA plays a complex role in patients with pigmentary retinal dystrophies and may be associated with VA and field decline as well as adverse side effects. Physicians should use caution with using VPA for pigmentary retinal dystrophies.
AB - Aims: The purpose of this study was to determine the long-term efficacy and safety of valproic acid (VPA) treatment in patients with pigmentary retinal dystrophies. Methods: A retrospective chart review was conducted on 31 patients with a diagnosis of pigmentary retinal dystrophy prescribed VPA at a single centre. Visual field (VF), visual acuity (VA), length of treatment, liver enzymes and side effects were analysed. VF areas were defined using Goldmann VF (GVF) tracings recorded before, during and after VPA treatment using the V4e isopter for each eye. Using custom software, planimetric areas of VF were calculated. Results: Five of the patients (10 eyes) had two Goldmann VF tracings, allowing comparison between baseline and follow-up VF. After 9.8 months of VPA, VF decreased by 0.145 cm2 (26.478%) (p=0.432). For 22 of the patients (41 eyes), VA data was available, and logarithm of the minimum angle of resolution (logMAR) score changed by 0.056 log units (representing a decline in VA) after 14.9 months on VPA (p=0.002). Twelve patients (38.7%) reported negative side effects related to VPA use. Conclusions: VPA plays a complex role in patients with pigmentary retinal dystrophies and may be associated with VA and field decline as well as adverse side effects. Physicians should use caution with using VPA for pigmentary retinal dystrophies.
UR - http://www.scopus.com/inward/record.url?scp=84879416452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879416452&partnerID=8YFLogxK
U2 - 10.1136/bjophthalmol-2013-303084
DO - 10.1136/bjophthalmol-2013-303084
M3 - Article
C2 - 23603755
AN - SCOPUS:84879416452
SN - 0007-1161
VL - 97
SP - 895
EP - 899
JO - British Journal of Ophthalmology
JF - British Journal of Ophthalmology
IS - 7
ER -